In this edition:
GAIA/CLL13: final analysis of venetoclax combinations in untreated CLL
STARGLO: 2-year analysis of Glofit-GemOx vs. R-GemOx in R/R DLBCL
FLAIR: MRD-guided duration of ibrutinib-venetoclax in untreated CLL
CaDAnCe-101: BGB-16673 (BTK degrader) in R/R CLL/SLL
CAPTIVATE: final analysis of fixed-duration ibrutinib-venetoclax in chronic CLL/SLL
Cyclophosphamide vs. methotrexate in untreated large granular lymphocyte leukaemia
ECHO: bendamustine-rituximab ± acalabrutinib in high-risk MCL
POLARGO: Pola-R-GemOx vs. R-GemOx in ASCT-ineligible R/R DLBCL
MorningSun: first-line subcutaneous mosunetuzumab in symptomatic marginal zone lymphoma
EPCORE NHL-2: epcoritamab + R-ICE in ASCT-eligible R/R DLBCL
Please login below to download this issue (PDF)